For U.S. Healthcare Professionals Only
Register for Samples

Savings offers for your patients whether commercially insured or not

Toujeo® savings offer for commercially insured patients

100% of your commercially insured patients can get their first 3 fills for a $0 co-pay,* with subsequent fills for a $10 co-pay each, regardless of formulary status and restrictions.

*Eligibility restrictions and offer terms apply. See details.

If you have any questions about starting your patients right away, please call 855-443-1577.

  • The co-pay card is accepted at retail pharmacies nationwide
  • Patients using a mail order pharmacy can still use this savings offer if they activate a copay card and submit for a rebate up to the maximum savings limit. See more at PatientRebateOnline.com or call 866-390-5622

If you or your office needs additional information call 855-443-1577
8 AM - 8 PM ET M-F
(except holidays)

Toujeo® Savings offer for patients without insurance

If your patients don’t have prescription medication insurance, they can use the Insulins Valyou Savings Program:

  • Your patients pay $99 for their monthly supply of any Sanofi Insulins*
  • Guaranteed one monthly set price for up to 10 vials or packs of pens per fill of any one or combination of Sanofi Insulins
  • Sanofi Insulins included in this program are: TOUJEO® (insulin glargine injection) 300 Units/mL, LANTUS® (insulin glargine injection) 100 Units/mL, APIDRA® (insulin glulisine injection) 100 Units/mL, and ADMELOG® (insulin lispro injection).
  • This offer is not valid for the Toujeo Max SoloStar pen and SOLIQUA 100/33 (insulin glargine and lixisenatide injection) 100 Units/mL and 33 mcg/mL.
  • Patients must fill all their Sanofi Insulin prescriptions at the same time, together each month.
  • The Insulins Valyou Savings Program applies to the cost of medication. There are other relevant costs associated with overall treatment.
  • Learn More or
    • > Phone: Uninsured patients should call the Insulins Valyou Savings Program - 833-813-0190 or
    • > Mail Order: Patients should activate their Insulins Valyou Savings Card before ordering and then submit a direct membership reimbursement (DMR) form. To get a DMR form, patients can visit PatientRebateOnline.com or call 833-813-0190

*Eligibility restrictions and offer terms apply. See details

Compare and save

An example compared with Tresiba®, Levemir®, and Basaglar®†

For a patient without insurance that needs two packs of pens per month their cost of Tresiba would be $1,224

With the Insulins Valyou savings Program, they get their monthly supply of Toujeo for $99 per month.

Toujeo prices listed are with the use of the Insulins Valyou Savings Program savings card. Prices for Basaglar, Levemir and Tresiba reflect GoodRx pricing on May 15, 2019. GoodRx is a widely used prescription savings program. This is for example purposes only. Different websites and pharmacies will have different pricing. Pricing is subject to change, so be sure to visit prescription savings program websites to find the latest pricing options.

The Insulins Valyou Savings Program applies to the cost of medication. There are other relevant costs associated with overall treatment. The products listed are not therapeutically equivalent and are not interchangeable.

If your patients need additional financial assistance, click here

Learn about Savings Offers on other Sanofi Insulins

Mail-order pharmacies?

Your patients using a mail order pharmacy can still use this savings offer if they activate a copay card and submit for a rebate up to the maximum savings limit.

Need help with the prior authorization process?

Sanofi Patient Connection can help your office obtain prior authorizations for Toujeo

Samples available

Register for samples today§—ordering has never been easier

§US licensed prescribers are required to register to request samples.

Need patient support?

Learn about tailored support from the Toujeo COACH Program

Toujeo is a long-acting human insulin analog indicated to improve glycemic control in adults with diabetes mellitus.

Limitations of Use: Toujeo is not recommended for treating diabetic ketoacidosis.

Important Safety Information for Toujeo® (insulin glargine injection) 300 Units/mL

Contraindications

Toujeo is contraindicated during episodes of hypoglycemia and in patients hypersensitive to insulin glargine or any of its excipients.

Warnings and Precautions

Toujeo contains the same active ingredient, insulin glargine, as Lantus®. The concentration of insulin glargine in Toujeo is 300 units per mL.

Insulin pens and needles must never be shared between patients. Do NOT reuse needles.

Monitor blood glucose in all patients treated with insulin. Modify insulin regimens cautiously and only under medical supervision. Changes in insulin strength, manufacturer, type, or method of administration may result in the need for a change in insulin dose or an adjustment in concomitant oral antidiabetic treatment. Changes in insulin regimen may result in hyperglycemia or hypoglycemia.

Unit for unit, patients started on, or changed to, Toujeo required a higher dose than patients controlled with Lantus. When changing from another basal insulin to Toujeo, patients experienced higher average fasting plasma glucose levels in the first few weeks of therapy until titrated to their individualized fasting plasma glucose targets. Higher doses were required in titrate-to-target studies to achieve glucose control similar to Lantus.

Hypoglycemia is the most common adverse reaction of insulin therapy, including Toujeo, and may be life-threatening.

Medication errors, such as accidental mix-ups between basal insulin products and other insulins, particularly rapid-acting insulins, have been reported. Patients should be instructed to always verify the insulin label before each injection.

Do not dilute or mix Toujeo with any other insulin or solution. If mixed or diluted, the solution may become cloudy, and the onset of action/time to peak effect may be altered in an unpredictable manner. Do not administer Toujeo via an insulin pump or intravenously because severe hypoglycemia can occur.

Severe life-threatening, generalized allergy, including anaphylaxis, can occur. Discontinue Toujeo, monitor and treat if indicated.

A reduction in the Toujeo dose may be required in patients with renal or hepatic impairment.

As with all insulins, Toujeo use can lead to life-threatening hypokalemia. Untreated hypokalemia may cause respiratory paralysis, ventricular arrhythmia, and death. Closely monitor potassium levels in patients at risk of hypokalemia and treat if indicated.

Fluid retention, which may lead to or exacerbate heart failure, can occur with concomitant use of thiazolidinediones (TZDs) with insulin. These patients should be observed for signs and symptoms of heart failure. If heart failure occurs, dosage reduction or discontinuation of TZD must be considered.

Drug Interactions

Certain drugs may affect glucose metabolism, requiring insulin dose adjustment and close monitoring of blood glucose. The signs of hypoglycemia may be reduced in patients taking anti-adrenergic drugs (eg, beta-blockers, clonidine, guanethidine, and reserpine).

Adverse Reactions

Adverse reactions commonly associated with Toujeo include hypoglycemia, allergic reactions, injection site reactions, lipodystrophy, pruritus, rash, edema and weight gain.

Important Safety Information for Toujeo® (insulin glargine injection) 300 Units/mL SoloStar® and Toujeo Max SoloStar

Toujeo SoloStar and Toujeo Max SoloStar are disposable prefilled insulin pens. To help ensure an accurate dose each time, patients should follow all steps in the Instruction Leaflet accompanying the pen; otherwise they may not get the correct amount of insulin, which may affect their blood glucose levels. It is especially important to perform a safety test when a patient is using a new pen for the first time.

Do not withdraw Toujeo from the SoloStar and Max SoloStar disposable prefilled pens with a syringe.

All registered trademarks cited are property of their respective owners.

*

*This offer is not valid for prescriptions covered by or submitted for reimbursement under Medicare, Medicaid, VA, DOD, or TRICARE, or similar federal or state programs, including any state pharmaceutical programs. Please note: the Federal Employees Health Benefits (FEHB) Program is not a federal or state government health care program for purposes of this savings program. Void where prohibited by law. Upon registration, patients receive all program details. Sanofi US reserves the right to change the maximum cap amount, rescind, revoke, or amend the program without notice.

  • First 3 fills for $0, next 12 consecutive fills for $10
  • Maximum savings up to $600 per box, up to 3 boxes

*Eligibility Restrictions & Offer Terms:

Insulins Valyou Savings Program:

Sanofi insulins included in this program are: ADMELOG® (insulin lispro injection), TOUJEO® (insulin glargine injection) 300 Units/mL, LANTUS® (insulin glargine injection) 100 Units/mL and APIDRA® (insulin glulisine injection) 100 units/mL. This offer is not valid for prescriptions covered by or submitted for reimbursement under Medicare, Medicaid, VA, DOD, TRICARE, similar federal or state programs, including any state pharmaceutical programs, or commercial / private insurance. Only people without prescription medication insurance can apply for this offer. Void where prohibited by law. For the duration of the program, eligible patients will pay $99 for up to 10 vials or packs of pens per fill. Offer is valid for one fill per month. To pay $99 per month, you must fill all your Sanofi Insulin prescriptions at the same time, together each month. Not valid for SOLIQUA 100/33 (insulin glargine and lixisenatide injection) 100 Units/mL and 33 mcg/mL or Toujeo Max SoloStar pen. When using the Insulins Valyou Savings Card, prices are guaranteed for 12 consecutive monthly fills. The Insulins Valyou Savings Program applies to the cost of medication. There are other relevant costs associated with overall treatment.

Sanofi Copay Program:

This offer is not valid for prescriptions covered by or submitted for reimbursement under Medicare, Medicaid, VA, DOD, TRICARE, or similar federal or state programs including any state pharmaceutical assistance program. Important to note that if you have an Affordable Care (Health Care Exchange) plan, you may still be qualified to receive and use this savings card. Please note: the Federal Employees Health Benefits (FEHB) Program is not a federal or state government health care program for purposes of the savings program. Void where prohibited by law.

  • Toujeo: $0 copay for the first 3 fills, then $10 copay for the next 12 fills. Maximum savings up to $600 per pack up to 3 packs per fill;

Savings may vary depending on patients’ out-of-pocket costs. Upon registration, patients receive all program details. Sanofi US reserves the right to change the maximum cap amount, rescind, revoke or amend these programs without notice.

© 2019 sanofi-aventis U.S. LLC. All rights reserved.

Legal Disclaimer | Privacy Policy | Contact SANOFI

This site is intended for use by U.S. Healthcare Professionals only.

SAUS.TJO.19.0569c(1) Last Update: May 2019

Important Safety Information for Toujeo® (insulin glargine injection) 300 Units/mL

Important Safety Information

Contraindications

Toujeo is contraindicated during episodes of hypoglycemia and in patients hypersensitive to insulin glargine or any of its excipients.

Warnings and Precautions

Toujeo contains the same active ingredient, insulin glargine, as Lantus®. The concentration of insulin glargine in Toujeo is 300 units per mL.

Insulin pens and needles must never be shared between patients. Do NOT reuse needles.

Monitor blood glucose in all patients treated with insulin. Modify insulin regimens cautiously and only under medical supervision. Changes in insulin